Clinical Trial Update: Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describes a functionally optimized CD33 CAR-T cell therapy targeting recurrent/refractory acute myeloid leukemia, currently not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD33 CAR-T cell therapy (functionally optimized)

Snippet

Sponsor: Qi deng | Conditions: CAR T Cell Therapy, CD33 Positive Acute Myelogenous Leukemia | Phase 1 | Status: NOT_YET_RECRUITING